Vibrio parahaemolyticus, a Gram-negative motile bacterium that inhabits marine and estuarine environments throughout the world, is a major food-borne pathogen that causes life-threatening diseases in humans after the consumption of raw or undercooked seafood. The global occurrence of V. parahaemolyticus accentuates the importance of investigating its virulence factors and their effects on the human host. This review describes the virulence factors of V. parahaemolyticus reported to date, including hemolysin, urease, two type III secretion systems and two type VI secretion systems, which both cause both cytotoxicity in cultured cells and enterotoxicity in animal models. We describe various types of detection methods, based on virulence factors, that are used for quantitative detection of V. parahaemolyticus in seafood. We also discuss some useful preventive measures and therapeutic strategies for the diseases mediated by V. parahaemolyticus, which can reduce, to some extent, the damage to humans and aquatic animals attributable to V. parahaemolyticus. This review extends our understanding of the pathogenic mechanisms of V. parahaemolyticus mediated by virulence factors and the diseases it causes in its human host. It should provide new insights for the diagnosis, treatment, and prevention of V. parahaemolyticus infection.

Macrophages exist in various tissues, several body cavities, and around mucosal surfaces and are a vital part of the innate immune system for host defense against many pathogens and cancers. Macrophages possess binary M1/M2 macrophage polarization settings, which perform a central role in an array of immune tasks via intrinsic signal cascades and, therefore, must be precisely regulated. Many crucial questions about macrophage signaling and immune modulation are yet to be uncovered. In addition, the clinical importance of tumor-associated macrophages is becoming more widely recognized as significant progress has been made in understanding their biology. Moreover, they are an integral part of the tumor microenvironment, playing a part in the regulation of a wide variety of processes including angiogenesis, extracellular matrix transformation, cancer cell proliferation, metastasis, immunosuppression, and resistance to chemotherapeutic and checkpoint blockade immunotherapies. Herein, we discuss immune regulation in macrophage polarization and signaling, mechanical stresses and modulation, metabolic signaling pathways, mitochondrial and transcriptional, and epigenetic regulation. Furthermore, we have broadly extended the understanding of macrophages in extracellular traps and the essential roles of autophagy and aging in regulating macrophage functions. Moreover, we discussed recent advances in macrophages-mediated immune regulation of autoimmune diseases and tumorigenesis. Lastly, we discussed targeted macrophage therapy to portray prospective targets for therapeutic strategies in health and diseases.

Since the development of antibody-production techniques, a number of immunoglobulins have been developed on a large scale using conventional methods. Hybridoma technology opened a new horizon in the production of antibodies against target antigens of infectious pathogens, malignant diseases including autoimmune disorders, and numerous potent toxins. However, these clinical humanized or chimeric murine antibodies have several limitations and complexities. Therefore, to overcome these difficulties, recent advances in genetic engineering techniques and phage display technique have allowed the production of highly specific recombinant antibodies. These engineered antibodies have been constructed in the hunt for novel therapeutic drugs equipped with enhanced immunoprotective abilities, such as engaging immune effector functions, effective development of fusion proteins, efficient tumor and tissue penetration, and high-affinity antibodies directed against conserved targets. Advanced antibody engineering techniques have extensive applications in the fields of immunology, biotechnology, diagnostics, and therapeutic medicines. However, there is limited knowledge regarding dynamic antibody development approaches. Therefore, this review extends beyond our understanding of conventional polyclonal and monoclonal antibodies. Furthermore, recent advances in antibody engineering techniques together with antibody fragments, display technologies, immunomodulation, and broad applications of antibodies are discussed to enhance innovative antibody production in pursuit of a healthier future for humans.

No abstract

Dear Editor, CRISPR-Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins) systems are RNA-guided adaptive immune systems in prokaryotes. 1,2 Class 2 CRISPR-Cas systems (including type II, V, and VI) involve large single effector proteins in complex with crRNA for interference. 3,4 The type II and V effectors, such as Cas9 and Cas12a, have been engineered into powerful tools for genome editing. The type VI system encompasses RNA-guided RNases. Its effectors Cas13a, Cas13b and Cas13d are capable of both precursor CRISPR RNA (pre-crRNA) processing and target RNA cleavage, which protect the host from phage attacks. 5-7 Once bound to a target RNA, they are activated, switching on a non-specific RNase activity. Moreover, they have been utilized to target and edit RNA as programmable RNAbinding modules. 6,[8][9][10][11][12] Although related to Cas13a and Cas13d, Cas13b possesses many distinctive features. These include the lack of significant sequence similarity with Cas13a and Cas13d, disparate crRNA repeat region, double-sided protospacer flanking sequence (PFS)-dependent target RNA cleavage. [5][6][7][8]13 To investigate how Cas13b processes pre-crRNA, recognizes crRNA and settles the spacer nucleotides for target recognition, we solved the crystal structure of Bergeyella zoohelcum Cas13b (BzCas13b) in complex with its crRNA at 2.79 Å resolution (Supplementary information, Table S1). The binary complex was obtained by the SeMet-derived BzCas13b R1177A mutant co-expressed with CRISPR template in vivo. The architecture of BzCas13b assumes a triangular domain distribution around the central L-shaped crRNA ( Fig. 1a-e; Supplementary information, Movie S1). In the binary complex, Helical-1, HEPN-1 and HEPN-2 domains together form one side of the triangular structure. Helical-1 domain comprises six α-helices connected with random loops (Supplementary information, Fig. S1). The second side of the triangle is formed by RRI-1 (the repeat region interacting domain-1), RRI-2 domains and the linker region. RRI-1 domain can be subdivided into two separate motifs (RRI-1 I and II) that stack onto each other. Both motifs contain a short twostranded, antiparallel β-sheet flanked by five α-helices. RRI-2 domain includes a long central two-stranded, antiparallel β-sheet flanked by two α-helices, and a short central two-stranded, antiparallel β-sheet flanked by three α-helices. The linker region consists of random loops that connect two short α-helices, which shows multiple interactions with RRI-2 domain. Helical-2 domain is composed of nine α-helices and its rather long helix-23 extends in parallel with crRNA, thereby forming the third side of the triangle. Helix-8 of Helical-1 domain and helix-23 of Helical-2 domain protrude out of the complex in a crab claw-like manner to clamp the spacer region of crRNA (Supplementary information, Fig. S1). In addition, HEPN-1 domain bridges Helical-1 and Helical-2 domains.A mature 52-nt crRNA, originated from a co-expressed CRISPR encoding sequence and bein...